**Core Concept**
The patient's anaemia is likely due to a deficiency of erythropoietin, a hormone produced by the kidneys that stimulates red blood cell production. In renal failure, erythropoietin production is impaired, leading to anaemia.

**Why the Correct Answer is Right**
The correct answer is a recombinant human erythropoietin (rHuEPO) analog, which replaces the deficient hormone and stimulates red blood cell production. This treatment is indicated in patients with chronic renal failure who have anaemia not responding to iron therapy. Erythropoietin stimulates the proliferation and differentiation of erythroid progenitor cells in the bone marrow, leading to an increase in red blood cell production.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not address the underlying cause of anaemia in renal failure. While erythropoietin-stimulating agents are a common treatment, this option does not specify a particular type of agent.
**Option B:** This option is incorrect because it is a type of medication that is not typically used to treat anaemia in renal failure. It may be used to treat other conditions, such as hypertension or heart failure.
**Option C:** This option is incorrect because it does not address the underlying cause of anaemia in renal failure. While iron therapy is often used to treat iron-deficiency anaemia, it does not replace the deficient erythropoietin hormone.

**Clinical Pearl / High-Yield Fact**
It's essential to note that erythropoietin-stimulating agents should be used in conjunction with iron therapy to maximize their effectiveness. Additionally, patients on these agents should be monitored regularly for signs of hypertension and thrombosis.

**Correct Answer:** C.